S
SYROS PHARMACEUTICALS INC
NASDAQ: SYRS (Syros Pharmaceuticals, Inc.)
Last update: 8 hours ago0.000
0.00 (0.00%)
| Avg. Volume (3M) | 11,128 |
| Market Cap | 2,683 |
| Price / Sales | 0.010 |
| Price / Book | 10.65 |
| 52 Weeks Range |
| Operating Margin (TTM) | -28,891.71% |
| Diluted EPS (TTM) | -3.07 |
| Current Ratio (MRQ) | 2.25 |
| Operating Cash Flow (TTM) | -100.02 M |
| Levered Free Cash Flow (TTM) | -57.94 M |
| Return on Assets (TTM) | -59.88% |
| Return on Equity (TTM) | -776.96% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Syros Pharmaceuticals, Inc. | Mixed | Mixed |
AIStockmoo Score
0.2
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 0.0 |
| Average | 0.17 |
|
Syros Pharmaceuticals Inc is a biopharmaceutical company committed to developing new standards of care for the frontline treatment of patients with hematologic malignancies. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 0.74% |
| % Held by Institutions | 11.48% |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |